O slideshow foi denunciado.
Seu SlideShare está sendo baixado. ×
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Anúncio
Próximos SlideShares
Blood coagulation
Blood coagulation
Carregando em…3
×

Confira estes a seguir

1 de 44 Anúncio

Mais Conteúdo rRelacionado

Diapositivos para si (20)

Semelhante a Hemostasis (20)

Anúncio

Mais de katejohnpunag (20)

Mais recentes (20)

Anúncio

Hemostasis

  1. 1. Hemostasis Cynthia J. Rutherford, M.D. Hematology-Oncology Division January 28, 2015
  2. 2. Phases of hemostasis • Primary hemostasis – platelet adhesion and aggregation • platelet number and function • von Willebrand factor • Secondary hemostasis – activation of the coagulation system • extrinsic • intrinsic • common pathway
  3. 3. The bleeding patient Clues from the history • Life long history of bleeding • Family history of bleeding • History of liver disease • History of hematologic disorder – ITP, leukemia • Medication history – ASA, NSAIDS . . .
  4. 4. The bleeding patient Clues from the physical exam • Pattern of skin and mucosal bleeding seen in defects of primary hemostasis - suggest thrombocytopenia, platelet defect or vWD • Pattern of muscle/deep bleeding suggesting defect in secondary hemostasis - coagulopathy • Stigmata of liver disease – arterial nevi, splenomegaly, palmar erythema • Pattern and clinical scenario of DIC
  5. 5. Clues from the physical exam Primary hemostatic defects PetechiaeBruising
  6. 6. Clues from the physical exam Severe primary hemostatic defects Mucosal bleeding = “wet” purpura
  7. 7. Clues from the physical exam Secondary hemostatic defects Hemophiliac joint bleed Deep muscle bleed r/o compartment syndrome
  8. 8. Clues from the physical examination Acute DIC
  9. 9. Patient with hemostatic defect Iatrogenic bleeding from IM injection
  10. 10. Laboratory evaluation of the bleeding patient • Hemoglobin/hematocrit – to assess effect of bleeding • Platelet count – bruising below 50K – bleeding below 10-20K • Platelet function – PFA-100 – Replaces “bleeding time” • Basic tests of coagulation – PT, PTT – Use these to guide specific factor testing
  11. 11. PFA-100 testing Platelet Function Analyzer Tests 1º hemostasis with collagen-ADP and collagen- epinephrine agonists Very sensitive (90%) for - vWD diagnosis - platelet dysfunction Useful in monitoring DDAVP therapy
  12. 12. PT PTT
  13. 13. Common causes of coagulopathy • Advanced liver disease – especially low factor VII – liver makes all coagulation factors, except factor VIII • Anticoagulants – Warfarin inhibits factor II, VII, IX and X – “new” oral anticoagulants – anti-Xa and anti thrombin inhibitors • DIC • Von Willebrand disease • Hemophilia • Other inherited factor deficiencies – afibrinogenemia, factor VII deficiency, etc. • Coagulation inhibitors
  14. 14. Treating the common causes of coagulopathy • Advanced liver disease – especially low factor VII Treat only with bleeding • Disseminated intravascular coagulation (DIC) – Treat cause – Maintain circulation – Transfuse platelets if platelets <50K and patient is bleeding, aiming to maintain platelets 50-75K – Transfuse cryoprecipitate to keep fibrinogen >50mg/dL Note: Plasma infusion not often needed as other coagulation factors not as depleted as fibrinogen
  15. 15. Cryoprecipitate • Contains only – Fibrinogen – VIII and vWD factor – Factor XIII • Cryoprecipitate packs pooled from 5 donors • Short shelf life after thawing – 4 hours
  16. 16. Von Willebrand disease • Autosomal dominant inherited condition • Reduced or dysfunctional von Willebrand factor affects: – Platelet adhesion and aggregation – Initiation of secondary hemostasis – Transport of factor VIII
  17. 17. Primary hemostasis •vWF •Factor VIII •Endothelial Cell •Endothelial •Cell •Unactivated •gpIIb/IIIa •Circulating •Platelet •Subendothelium •(Exposed Collagen) •gpIb/IX •Ligand
  18. 18. Primary hemostasis Aggregation of activated platelets •Fibrinogen •Activated Platelet •Activated gpIIb/IIIa
  19. 19. Von Willebrand’s original family
  20. 20. Classification of von Willebrand’s Disease Type 1 Quantitative deficiency of vWF 75-80% Autosomal dominant Type 2 Qualitative deficiency of vWF 15-20% Autosomal dominant Type 3 Absence of vWF 1:1,000,000 Autosomal recessive
  21. 21. Laboratory Diagnosis of von Willebrand Disease • General screening tests – PFA – 100 (replaces bleeding time) – Activated partial thromboplastin time • Tests specific to vWD – Factor VIII coagulant function – vW factor antigen – vW factor (Ristocetin co-factor) assay – Ristocetin-induced platelet aggregation – vW factor Multimer analysis
  22. 22. Type 2 vWD: Qualitative Abnormalities in vWF Type 2A Impaired secretion or increased proteolysis Absence of large and intermediate multimers Type 2B Increased affinity for gpIb Absence of large multimers Type 2M Decreased platelet-dependent function Normal multimer pattern Type 2N Decreased affinity for factor VIII Normal multimers
  23. 23. Patterns of multimers in von Willebrand disease subtypes •Largest Multimers •Intermediate •Multimers •Small Multimers •Normal •Type I •Type IIA •Type IIB •Type III
  24. 24. Treatment of von Willebrand Disease • DDAVP to release vWF from endothelial cells and platelets • Replacement of vWF with plasma-derived products - Humate-P, Alphanate or Wilate • Prevention of fibrinolysis – mucous membrane bleeding only – e-amino caproic acid (Amicar® ) • General measures – estrogens, topical agents
  25. 25. DDAVP in von Willebrand’s Disease Releases stored DDAVP from endothelial cells Increases vWF 2-3 fold – need therapeutic trial Route Dose Time to Peak Intravenous 0.3 µg/Kg 30 minutes Intranasal 300 µg 60 minutes • Side effects: flushing, headache, hyponatremia, ? myocardial infarction • Modest tachyphylaxis
  26. 26. Hemophilia Inherited deficiency or dysfunction of factor: VIII Hemophilia A 85% (Classic hemophilia) IX Hemophilia B 15% (Christmas disease)
  27. 27. Types of Hemophilia # in # in TYPE FACTOR INCIDENCE USA TEXAS Hemophilia A VIII 1:7000 17,500 1100 (Classical hemophilia) Hemophilia B IX 1:30,000 4000 250 (Christmas disease)
  28. 28. Signs and Symptoms of Hemophilia • Hemarthroses – joint bleeding • Muscle hemorrhage • Soft tissue hematomas • CNS bleeding • Uncommon: epistaxis, other mucosal bleeding, prolonged bleeding from cuts, petechiae
  29. 29. Hemophilia Genetics • X-linked recessive inheritance • Disease almost exclusively in males • High rate of spontaneous mutation – one third new cases have negative family history • Carrier testing & pre-natal diagnosis available (RFLP)
  30. 30. Degrees of Severity of Hemophilia Factor level Frequency and Severity Type (Normal 50-150%) of bleeding of bleeding Severe <1% 30-50 times per year Spontaneous Moderate 1-5% 3-10 times per year Occ spontaneous, usually post trauma Mild 5-30% <1 per year Post-trauma or surgery only
  31. 31. Signs and Symptoms of Hemophilia • Soft tissue hematomas • Hemarthroses • Muscle hemorrhage • CNS bleeding • Uncommon: epistaxis, other mucosal bleeding, prolonged bleeding from cuts, petechiae
  32. 32. Spontaneous Head “Bump” Severe Hemophilia
  33. 33. Hemophilic Arthropathy
  34. 34. Hemophilic Arthropathy
  35. 35. Forearm Compartment Bleed •Volkman’s ischemic contracture•Compartment syndrome
  36. 36. Iatrogenic Complications in hemophilia •Circumcision •i.m. injection •i.j. stick
  37. 37. Ilio-Psoas Hemorrhage
  38. 38. Laboratory Diagnosis of Hemophilia • aPTT Prolonged • Prothrombin time - INR Normal • (Bleeding time) Normal • PFA-100 Normal • Platelet count Normal • von Willebrand factor Normal • Factor VIII One or the other • Factor IX reduced•}
  39. 39. Treatment in hemophilia • For mild hemophilia A – always consider DDAVP – will raise factor level 2-3X • Factor replacement in doses related to the severity of the bleed or procedure
  40. 40. Hemophilia Factor VIII and IX Concentrates • Heat or solvent-detergent treated – “intermediate” purity factors, e.g. Humate-P • Purified with – Monoclonal antibodies – Chromatography • Recombinant factors • In 2014 – factors with longer T1/2
  41. 41. Major Emergencies in Hemophilia • Intra-cranial hemorrhage • Iliopsoas hemorrhage • Bleeding around airway • Uncontrolled external bleeding
  42. 42. Management “pearls” for hemophiliacs in the ER • Most patients are very knowledgeable about their disease, its treatment with concentrate and which veins are best for infusion • Laboratory testing (PT/PTT, factor assays, CBC, etc.) or x-rays (e.g, of joints) not routinely necessary • Following trauma or when any serious illness is suspected, treat with factor concentrates first and then do laboratory tests and x-rays
  43. 43. The bleeding patient • Don’t panic! • Try to figure the cause from history and physical examination • Order laboratory tests before blood or other products given • Ask for help – there’s a lot of it around!
  44. 44. Questions?

×